Citations

ABSTRACTBackground and AimsOne strategy to minimize the risk of posttransplant lymphoproliferative disorder (PTLD) is to avoid an Epstein–Barr Virus (EBV) mismatch through kidney paired donation. We aimed to estimate the incidence of PTLD in EBV‐negative kidney transplant recipients with EBV‐positive donors (D+/R−) and evaluate the excess risk of death following the occurrence of PTLD.MethodsWe included adult patients in OPTN database who underwent kidney transplants between 2012 and 2022. Cox regression analysis was employed to evaluate the impact of EBV serostatus on the development of PTLD, and to assess mortality following PTLD diagnosis in D+/R− individuals.ResultsA total of 179 068 patients were included, with 92.8% in the R+, 6.4% in the D+/R−, and 0.8% in the D−/R− group. D+/R− exhibited a significantly higher risk of PTLD compared to R+ and D−/R− groups. D+/R− had a greater risk of PTLD when compared to D−/R− recipients (aHR: 3.82; p < 0.001). Among D+/R− recipients, those who developed PTLD had a significantly higher risk of mortality (aHR: 2.28; p < 0.001 in deceased donor kidney transplant [DDKT] and aHR: 5.22; p < 0.001 in living donor kidney transplant [LDKT]).ConclusionsD+/R− recipients have nearly a fourfold higher risk of PTLD compared to D−/R− recipients, suggesting that choosing an EBV D−/R− transplant could reduce the PTLD risk by about 73%. This data is crucial for counseling EBV‐negative patients considering kidney paired donation to avoid an EBV serostatus mismatch.

Emerging evidence supports the beneficial effects of dietary fiber supplementation in alleviating gut dysbiosis, which leads to a reduction in uremic toxins and inflammatory markers in chronic kidney disease (CKD) patients. However, current evidence-based renal nutrition guidelines do not provide recommendations regarding dietary fiber intake. We performed a systematic review and meta-analysis to investigate and highlight the effects of dietary fiber supplementation on modulating uremic toxins and inflammatory markers in individuals with CKD, with or without dialysis. The eligible randomized controlled trials (RCTs) were identified from PubMed, Scopus, and Cochrane Central Register of Controlled trials until 27 November 2024. The results were synthesized using a random-effects model and presented as standardized mean differences (SMDs) with a 95% confidence interval (CI). A total of 21 studies with 700 patients were included. When compared with the control group, dietary fiber supplementation ranging from 6 to 50 g/day, for typically more than 4 weeks, could significantly reduce the levels of serum uremic toxins, including p-cresyl sulfate, indoxyl sulfate, and blood urea nitrogen (SMD −0.22, −0.34, −0.25, respectively, with p-values < 0.05), as well as biomarkers of inflammation, including interleukin-6 and tumor necrosis factor alpha (SMD −0.44, −0.34, respectively, with p-values < 0.05). These beneficial effects were consistent across different types of fibers and CKD status (with or without dialysis). However, no significant reduction in serum trimethylamine N-oxide, uric acid, and high-sensitivity C-reactive protein levels was observed with dietary fiber intervention. This study would pave the way for prioritizing dietary quality, particularly a fiber-rich diet, beyond the traditional focus on the quantities of protein, energy, and electrolyte restrictions among individuals with CKD.

Background/Objectives: It is often challenging for patients to understand treatment options, their mechanisms of action, and the potential side effects of each treatment option for glomerular disorders. This study explored the ability of ChatGPT to simplify these treatment options to enhance patient understanding. Methods: GPT-4 was queried on sixty-seven glomerular disorders using two distinct queries for a general explanation and an explanation adjusted for an 8th grade level or lower. Accuracy was rated on a scale of 1 (incorrect) to 5 (correct and comprehensive). Readability was measured using the average of the Flesch–Kincaid Grade (FKG) and SMOG indices, along with the Flesch Reading Ease (FRE) score. The understandability score (%) was determined using the Patient Education Materials Assessment Tool for Printable Materials (PEMAT-P). Results: GPT-4’s general explanations had an average readability level of 12.85 ± 0.93, corresponding to the upper end of high school. When tailored for patients at or below an 8th-grade level, the readability improved to a middle school level of 8.44 ± 0.72. The FRE and PEMAT-P scores also reflected improved readability and understandability, increasing from 25.73 ± 6.98 to 60.75 ± 4.56 and from 60.7% to 76.8% (p < 0.0001 for both), respectively. The accuracy of GPT-4’s tailored explanations was significantly lower compared to the general explanations (3.99 ± 0.39 versus 4.56 ± 0.66, p < 0.0001). Conclusions: ChatGPT shows significant potential for enhancing the readability and understandability of glomerular disorder therapies for patients, but at a cost of reduced comprehensiveness. Further research is needed to refine the performance, evaluate the real-world impact, and ensure the ethical use of ChatGPT in healthcare settings.